Merck Completes Acquisition of EyeBio, Advances Restoret™ for Retinal Diseases
Merck completes EyeBio acquisition, advancing Restoret™ for retinal diseases to pivotal trials.
Merck has completed the acquisition of Eyebiotech Limited
(EyeBio), making it a wholly-owned subsidiary of Merck.
"The acquisition of EyeBio enhances our late-stage
pipeline with a promising candidate grounded in novel biology and genetics for
treating certain retinal diseases," said Dr. Dean Y. Li, president of
Merck Research Laboratories. "We are thrilled to welcome the EyeBio team
and collaborate to advance Restoret for patients in need."
EyeBio’s lead candidate, Restoret™ (EYE103), is an
investigational tetravalent, tri-specific antibody that acts as an agonist of
the Wingless-related integration site (Wnt) signaling pathway. Following
positive outcomes from the open-label Phase 1b/2a AMARONE study in patients
with diabetic macular edema (DME) and neovascular age-related macular
degeneration (NVAMD), Restoret is set to enter a pivotal Phase 2b/3 trial for
DME treatment in the latter half of 2024.
EyeBio’s pipeline also includes clinical and preclinical
assets aimed at preventing and treating vision loss due to retinal vascular
leakage, a risk factor for retinal diseases.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion